Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

Wolowacz, Sorrel; Roskell, Neil; Maciver, Fiona; Beard, Stephen; Robinson, Paul A.; Plumb, Jonathan; Dolan, G.; Brenkel, Ivan J.

doi:10.1016/j.clinthera.2009.01.001

Cited by 69 publications

(56 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In regard to the cost-benefi t of the new oral anticoagulants, Wolowacz et al (2009) found that dabigatran was more cost-effective than enoxaparin when administered for patients following total knee and total hip arthroplasty surgery and held true even when patients concurrently injected themselves with enoxaparin for the short term. When using dabigatran for more than 30 days, dabigatran was not found to be as cost-effective as enoxaparin.…”

Section: Ost C Omparisonsmentioning

confidence: 96%

Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis

Welle

2012

Orthopaedic Nursing

View full text Add to dashboard Cite

Patients who have major orthopaedic surgery are at high risk for developing venous thromboembolism (VTE). Assessment of risk and treatment to prevent VTE are considered standard of care due to its significant morbidity, potential mortality, and clinical burden and cost. Guidelines are available aiding orthopaedic surgeons to choose the best methods of VTE prophylaxis. Optimal VTE prevention has not been achieved. Recent advances in the understanding of the coagulation cascade have evolved because of a novel understanding of the molecular influences on the coagulation pathway. Subsequently, new anticoagulants have been developed that target specific factors within the coagulation cascade that are contrasted to the currently used agents that have a broad effect on the coagulation pathway. Multiple clinical trials have tested the new anticoagulants within the orthopaedic total knee and total hip arthroplasty arena. In addition, research to find new ways to prevent VTE was driven by limitations of the currently available agents. The new oral anticoagulants extensively trialed in orthopaedics are dabigatran, rivaroxaban, and apixaban. Clinical trials indicate that the new oral agents have the potential to impact VTE prophylaxis in regard to efficacy, predictability and consistency, clinical monitoring, adherence as to use and duration, and convenience. Concerns persist regarding issues of bleeding complications, liver enzyme elevation, patients with renal disease, and drug-to-drug interactions. The new oral agents do not have an antidote to reverse bleeding effect and have no reliable assay to measure effect. Nurses need to be aware of these new VTE prophylactic choices and their implications in order to provide the best outcomes for their patients.

show abstract

Section: Ost C Omparisonsmentioning

confidence: 96%

Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis

Welle

2012

Orthopaedic Nursing

View full text Add to dashboard Cite

show abstract

“…In 2008 dabigatran was granted an approval in Europe and in Canada in the prevention of VTE after major orthopaedic surgery. Its perspective seems even more interesting when someone considers the pharmocoeconomics of the drug, since it has shown superiority when compared to other traditionally used anticoagulants as far costeffectiveness is concerned [98][99][100]. More studies are needed in order to establish a clear role of dabigatran in the treatment of VTE as well as in order to clarify its noninferiority or inferiority vs enoxaparin 30 mg BID in the prevention of venous thrombosis after major knee or hip surgery.…”

Section: Dabigatran In Venous Thromboembolismmentioning

confidence: 98%

Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants

Deftereos

Hatzis²,

Kossyvakis³

et al. 2012

CCP

View full text Add to dashboard Cite

Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, is the third most common cause of vascular death after myocardial infarction and stroke. Clinicians are often summoned to make challenging decisions for the prevention and treatment of high risk patients with an unpredicted outcome, often relying on data that are less than definitive. During the last decades, heparins (unfractionated and low molecular weight heparins) as well as vitamin K antagonists, such as warfarin, and indirect Xa inhibitors, such as fontaparinux, are the cornerstone for the prevention and treatment of patients with venous thromboembolism. However, the traditionally used anticoagulants have several drawbacks that may limit their efficacy and use in every day clinical practise. The newly developed oral anticoagulants, belonging to the categories of direct thrombin inhibitors (DTIs) and direct Xa inhibitors, have emerged as promising agents with remarkable efficacy, concentrating many parameters of an ideal anticoagulant. Rivaroxaban, dabigatran and apixaban are the most studied agents, while a plethora of others are investigated in clinical trials of different phases and are expected to reach the market in the following years. The purpose of this review is to summarize the so far acquired knowledge on these agents, to report briefly some of their pharmacodynamic and pharmacokinetic properties and to focus on their role in the treatment and prevention of venous thromboembolism.

show abstract

“…12-14 Decrements in quality of life associated with events were assumed to be the same regardless of surgery type, but the duration may vary. [8][9][10][11] Assumptions Several key structural assumptions must be borne in mind when evaluating the results of this model.…”

Section: Inputs and Data Sourcesmentioning

confidence: 99%

Anticoagulation Prophylaxis in Orthopedic Surgery: An Efficiency Frontier Approach

Migliaccio–Walle

Rublee

Simon

2012

Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

Cited by 69 publications

References 47 publications

Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis

Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis

Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants

Anticoagulation Prophylaxis in Orthopedic Surgery: An Efficiency Frontier Approach

Contact Info

Product

Resources

About